Trial Profile
A retrospective review to describe the Immune related adverse events associated with Ipilimumab and Nivolumab
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 10 Oct 2017
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Non-small cell lung cancer; Renal cell carcinoma; Skin cancer
- Focus Adverse reactions; Expanded access
- 10 Oct 2017 New trial record
- 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress